• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Perrigo Company plc

    2/13/24 1:05:29 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email
    SC 13G 1 prgo13g02132024.htm SCHEDULE 13G






    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    Under the Securities Exchange Act of 1934
    (Amendment No.         )*


    Perrigo Co PLC
    (Name of Issuer)


    Common Stock
    (Title of Class of Securities)


    G97822103
    (CUSIP Number)


    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)


    Check appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☑ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)


    *
     
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

    1


    CUSIP No. G97822103
     
     
     
     
      
      1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)
     
    Barrow Hanley Global Investors
    752403190
      2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a)  ☐
    (b)  ☐
      3.
    SEC USE ONLY
     
      4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    A Delaware limited liability company
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
      5.    SOLE VOTING POWER
     
                  shares
     
      6.    SHARED VOTING POWER
     
                  shares
      7.    SOLE DISPOSITIVE POWER
     
                  shares
      8.    SHARED DISPOSITIVE POWER
     
            —
       9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
          shares
    10.
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
     
    ☐
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
         %
    12.
    TYPE OF REPORTING PERSON (See Instructions)
     
    IA
     
     
    2

     
    SCHEDULE 13G
     
    Item 1(a)
      
    Name of Issuer: Perrigo Co PLC
       
    1(b)
      
    Address of Issuer’s Principal Executive Offices:
       
     
      
    The Sharp Building, Hogan Place
    Dublin 2, Ireland D02 TY74
       
    Item 2(a)
      
    Name of Person Filing:
         
       
    Barrow Hanley Global Investors
       
    2(b)
      
    Address of Principal Business Office or, if none, Residence:
       
     
      
    2200 Ross Avenue, 31st Floor
    Dallas, TX 75201-2761
       
    2(c)
      
    Citizenship:
       
     
      
    A Delaware limited liability company
     
     
    2(d)
      
    Title of Class of Securities
     
     
     
      
    Common Stock
     
     
    2(e)
      
    CUSIP Number:    G97822103
     
     
    Item 3
      
    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
     
     
     
     
     
      
    (a)
      
    ☐
      
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
     
     
     
     
      
    (b)
      
    ☐
      
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
     
     
     
     
      
    (c)
      
    ☐
      
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
     
     
     
     
      
    (d)
      
    ☐
      
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
     
     
     
     
      
    (e)
      
    ☑
      
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
     
     
     
     
      
    (f)
      
    ☐
      
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
     
     
     
     
      
    (g)
      
    ☐
      
    A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
     
     
     
     
     
      
    (h)
      
    ☐
      
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
     
     
     
     
      
    (i)
      
    ☐
      
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
     
     
     
     
      
    (j)
      
    ☐
      
    Group, in a accordance with §240.13d-1(b)(1)(ii)(J).
     
     
    3

    Item 4
      
    Ownership:
     
     
     
     
      
    4(a)
      
    Amount beneficially owned:        shares
     
     
     
     
      
    4(b)
      
    Percent of Class:       %
     
     
     
     
      
    4(c)
      
    Number of shares as to which person has:
     
     
      
     
    (i)
    Sole power to vote or to direct the vote:        shares

     
      
    (ii)
    Shared power to vote or to direct the vote:        shares
       
     
      
    (iii)
    Sole power to dispose or to direct the disposition of:        shares
       
     
      
    (iv)
    Shared power to dispose or to direct the disposition of:  —
       
    Item 5
      
    Ownership of Five Percent or Less of a Class:
     
      
     Yes.  
       
    Item 6
      
    Ownership of More than Five Percent on Behalf of Another Person:
     
      
    The right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the common stock is held by certain clients of the reporting person, none of which has such right or power with respect to five percent or more of the common stock.
     
     
    Item 7
      
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
     
      
    Not Applicable.
     
     
    Item 8
      
    Identification and Classification of Members of the Group:
     
      
    Not Applicable.
       
    Item 9
      
    Notice of Dissolution of Group:
     
      
    Not Applicable.
       
    Item 10
      
    Certification:
       
       
    By signing below the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     
    Barrow Hanley Global Investors
           
     
    By:
    /s/ Hannah Ackels
     
       
    Name:  Hannah Ackels
     
       
    Title:   Chief Compliance Officer
     
           
     
     February 13, 2024
    4
    Get the next $PRGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    11/11/2021$59.00 → $55.00Outperform
    Raymond James
    More analyst ratings

    $PRGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations

      Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN, May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested

      5/7/25 6:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Announces Quarterly Dividend

      DUBLIN, April 30, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit

      4/30/25 10:23:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025

      DUBLIN, April 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2025 financial results on Wednesday, May 7th, 2025, and host a conference call beginning at 8:30 A.M. (EST).  The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 04449. A taped replay o

      4/23/25 4:47:00 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Perrigo Company plc

      SC 13G - PERRIGO Co plc (0001585364) (Subject)

      10/31/24 11:55:03 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Perrigo Company plc

      SC 13G - PERRIGO Co plc (0001585364) (Subject)

      2/13/24 1:05:29 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Perrigo Company plc (Amendment)

      SC 13G/A - PERRIGO Co plc (0001585364) (Subject)

      1/24/24 2:27:16 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Andersen Svend bought $27,900 worth of Ordinary Shares (1,000 units at $27.90), increasing direct ownership by 0.99% to 101,853 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      5/31/24 5:04:45 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ives Alison exercised 1,698 units of Ordinary Shares at a strike of $27.26, covered exercise/tax liability with 1,262 units of Ordinary Shares and bought $67,877 worth of Ordinary Shares (2,490 units at $27.26), increasing direct ownership by 24% to 15,372 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      3/7/24 9:58:50 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ives Alison bought $40,850 worth of Ordinary Shares (1,545 units at $26.44), increasing direct ownership by 14% to 12,446 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      3/7/24 9:54:19 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    SEC Filings

    See more
    • SEC Form S-8 filed by Perrigo Company plc

      S-8 - PERRIGO Co plc (0001585364) (Filer)

      5/7/25 5:23:16 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Perrigo Company plc

      10-Q - PERRIGO Co plc (0001585364) (Filer)

      5/7/25 2:46:04 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Company plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PERRIGO Co plc (0001585364) (Filer)

      5/7/25 6:41:21 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

      For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

      7/13/23 8:32:15 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Leadership Updates

    Live Leadership Updates

    See more
    • Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

      Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s

      1/6/25 8:00:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary

      Atkinson joins Perrigo from Haleon plc, where he previously served as Interim General Counsel DUBLIN, Sept. 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. He is a skilled lawyer with nearly 25 years of experience, mostly within the regulated consumer self-care industry. President and CEO Patrick Lockwood-Taylor commented, "I am very excited to welcome Charles to the Perrigo leadership team. His strat

      9/4/24 8:00:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Appoints David Ball to the Newly Created Position of Executive Vice President and Chief Brand and Digital Officer

      DUBLIN, Aug. 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer. In this newly created position, Dr. Ball will be responsible for an enterprise-wide marketing strategy that incorporates deep understanding of consumer needs and translates those into winning brand strategies, tactics, and actions. He will also evaluate untapped market opportunities and develop strategies to scale the Company's brand-building efforts.

      8/19/24 8:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Financials

    Live finance-specific insights

    See more
    • Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations

      Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN, May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested

      5/7/25 6:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Announces Quarterly Dividend

      DUBLIN, April 30, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit

      4/30/25 10:23:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025

      DUBLIN, April 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2025 financial results on Wednesday, May 7th, 2025, and host a conference call beginning at 8:30 A.M. (EST).  The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 04449. A taped replay o

      4/23/25 4:47:00 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Perrigo downgraded by Argus

      Argus downgraded Perrigo from Buy to Hold

      1/14/25 8:38:48 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously

      1/6/25 8:24:36 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Perrigo with a new price target

      Jefferies resumed coverage of Perrigo with a rating of Hold and set a new price target of $30.00 from $50.00 previously

      9/24/24 8:23:03 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Samuelson Jonas

      4 - PERRIGO Co plc (0001585364) (Issuer)

      4/11/25 2:25:14 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Samuelson Jonas claimed no ownership of stock in the company (SEC Form 3)

      3 - PERRIGO Co plc (0001585364) (Issuer)

      4/11/25 10:58:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP and CSO Lennox Abigail

      4 - PERRIGO Co plc (0001585364) (Issuer)

      4/8/25 11:23:10 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care